IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab

PURPOSE: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome. PATIENTS AND METHODS: Serum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Marisi, Giorgia, Scarpi, Emanuela, Passardi, Alessandro, Nanni, Oriana, Pagan, Flavia, Valgiusti, Martina, Gardini, Andrea Casadei, Neri, Luca Maria, Frassineti, Giovanni Luca, Amadori, Dino, Ulivi, Paola
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6241685/
https://ncbi.nlm.nih.gov/pubmed/30532588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S181570
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados